Vaccinating with the genome: a Sisyphean task?

Trends in Parasitology

Volumn 25, Issue 5, 2009, Pages 205-212

  Coppel, Ross L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MALARIA VACCINE; MEMBRANE ANTIGEN;

ARTICLE; ERYTHROCYTE MEMBRANE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE REPLICATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALARIA; NONHUMAN; OPEN READING FRAME; PLASMODIUM FALCIPARUM; UNITED STATES; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; COMPUTATIONAL BIOLOGY; DRUG DESIGN; GENOME, PROTOZOAN; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

PLASMODIUM FALCIPARUM;

EID: 65249134014     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2009.02.006     Document Type: Article

References (55)

1. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185 (2002) 820-827
2. Sanders P.R., et al. A set of glycosylphosphatidyl inositol-anchored membrane proteins of Plasmodium falciparum is refractory to genetic deletion. Infect. Immun. 74 (2006) 4330-4338
3. Hudson D.E., et al. Molecular basis for mutation in a surface protein expressed by malaria parasites. J. Mol. Biol. 203 (1988) 707-714
4. Klotz F.W., et al. Vaccination-induced variation in the 140 kD merozoite surface antigen of Plasmodium knowlesi malaria. J. Exp. Med. 165 (1987) 359-367
5. Hillenmeyer M.E., et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320 (2008) 362-365
6. Triglia T., et al. An EBA175 homologue which is transcribed but not translated in erythrocytic stages of Plasmodium falciparum. Mol. Biochem. Parasitol. 116 (2001) 55-63
7. Drew D.R., et al. A common cross-species function for the double epidermal growth factor-like modules of the highly divergent plasmodium surface proteins MSP-1 and MSP-8. J. Biol. Chem. 279 (2004) 20147-20153
8. O'Donnell R.A., et al. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nat. Med. 6 (2000) 91-95
9. de Koning-Ward T.F., et al. Truncation of Plasmodium berghei merozoite surface protein 8 does not affect in vivo blood-stage development. Mol. Biochem. Parasitol. 159 (2008) 69-72
10. Crewther P.E., et al. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect. Immun. 64 (1996) 3310-3317
11. Lyon J.A., et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 3 (2008) e2830
12. Rotman H.L., et al. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp. Parasitol. 91 (1999) 78-85
13. Bejon P., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359 (2008) 2521-2532
14. Snape M.D., and Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect. Dis. 5 (2005) 21-30
15. Plebanski M., et al. Malaria vaccines: into a mirror, darkly?. Trends Parasitol. 24 (2008) 532-536
16. Penny M.A., et al. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS One 3 (2008) e3193
17. Sabchareon A., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45 (1991) 297-308
18. Cohen S., et al. Gamma-globulin and acquired immunity to human malaria. Nature 192 (1961) 733-737
19. Bergmann-Leitner E.S., et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am. J. Trop. Med. Hyg. 75 (2006) 437-442
20. Mullen G.E., et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One 3 (2008) e2940
21. Malkin E.M., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73 (2005) 3677-3685
22. Darko C.A., et al. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect. Immun. 73 (2005) 287-297
23. Guevara Patino J.A., et al. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 186 (1997) 1689-1699
24. Bouharoun-Tayoun H., et al. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182 (1995) 409-418
25. Badell E., et al. Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J. Exp. Med. 192 (2000) 1653-1660
26. McIntosh R.S., et al. The importance of human FcγRI in mediating protection to malaria. PLoS Pathog. 3 (2007) e72
27. Wang L., et al. An in vitro tool to assess the potential protective efficacy of Plasmodium yoelii MSP119-based immunisation regimens by measuring specific invasion inhibitory antibodies in mouse sera. Int. J. Parasitol. 38 Suppl. 1 (2008) S48
28. Druilhe P., et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2 (2005) e344
29. Oeuvray C., et al. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect. Immun. 68 (2000) 2617-2620
30. Villard V., et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS One 2 (2007) e645
31. Mullen G.E., et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24 (2006) 2497-2505
32. Egan A.F., et al. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21 (1999) 133-139
33. Polhemus M.E., et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25 (2007) 4203-4212
34. Thera M.A., et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One 3 (2008) e1465
35. Goschnick M.W., et al. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect. Immun. 72 (2004) 5840-5849
36. Langhorne J., et al. Immunity to malaria: more questions than answers. Nat. Immunol. 9 (2008) 725-732
37. al-Yaman F., et al. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol. 17 (1995) 493-501
38. Aide P., et al. Towards an effective malaria vaccine. Arch. Dis. Child. 92 (2007) 476-479
39. O'Donnell R.A., et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193 (2001) 1403-1412
40. John C.C., et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J. Immunol. 173 (2004) 666-672
41. Corran P.H., et al. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect. Immun. 72 (2004) 6185-6189
42. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22 (2004) 1393-1398
43. Clark E.D.B. Protein refolding for industrial processes. Curr. Opin. Biotechnol. 12 (2001) 202-207
44. Gardner M.J., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419 (2002) 498-511
45. Huestis R., and Fischer K. Prediction of many new exons and introns in Plasmodium falciparum chromosome 2. Mol. Biochem. Parasitol. 118 (2001) 187-199
46. Hiller N.L., et al. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science 306 (2004) 1934-1937
47. Marti M., et al. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science 306 (2004) 1930-1933
48. Sargeant T.J., et al. Lineage-specific expansion of proteins exported to erythrocytes in malaria parasites. Genome Biol. 7 (2006) R12
49. Foth B.J., et al. Dissecting apicoplast targeting in the malaria parasite Plasmodium falciparum. Science 299 (2003) 705-708
50. Waters A. Malaria: new vaccines for old?. Cell 124 (2006) 689-693
51. Cohen S., et al. Action of malarial antibody in vitro. Nature 223 (1969) 368-371
52. Haas G., et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2 (2002) 313-324
53. Havlasova J., et al. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics 5 (2005) 2090-2103
54. Osier F.H., et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 76 (2008) 2240-2248
55. Ma F., et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 13087-13092